NovoCure Limited

NVCR Healthcare Medical Devices

NovoCure Limited’s revenue for fiscal 2025 (year ended December 2025) was $655.4 million, up 8.28% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 63.9%, free cash flow grew 105.7% and total debt rose 100.7%, each against the same quarter a year earlier.

14.07 0.34 −2.36%
Market cap
$1.7B
P/E
0.0×
Fwd P/E
−10.8×
Dividend yield
—
F-score
4/9
Altman Z
0.43
Beneish M
−2.12
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
0.00 0.00 0.00 0.00 865.20 0.00 0.00 0.00 0.00 0.00
Piotroski F-Score
4 4 4 7 6 4 4 1 5 4
P/S ratio
8.10 10.15 12.39 23.32 35.33 14.51 13.22 3.01 5.31 2.20
Altman Z-Score
0.21 5.06 6.77 18.50 18.95 6.87 6.39 0.68 1.26 0.43
P/FCF ratio
0.00 0.00 0.00 507.85 207.47 132.55 754.04 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
(2.45) (2.55) (1.37) 1.27 4.63 3.73 3.23 1.21 (1.67) (2.29)
Beneish M-Score
(2.09) (1.93) (2.99) (0.43) (2.72) (3.18) (2.86) (3.14) (2.87) (2.12)
P/Operating CF
(48.94) (620.26) 182.85 1,176.99 326.57 539.14 (1,918.15) (105.24) (931.17) (80.06)
P/B ratio
4.72 15.83 27.39 37.62 36.65 18.92 16.12 4.23 8.92 4.23
Price to Tangible BV
4.72 15.83 27.39 37.62 36.65 18.92 16.12 4.23 8.92 4.23
EV/Sales
6.61 9.66 12.00 22.82 34.47 13.81 12.47 2.33 3.91 1.80
EV/EBITDA
0.00 0.00 0.00 1,492.64 398.05 0.00 0.00 0.00 0.00 0.00
EV/Operating CF
(5.09) (51.59) (1,595.53) 301.11 171.87 89.29 217.82 (16.21) (89.82) (24.04)
EV/FCF
(4.37) (42.21) (346.97) 496.77 202.43 126.13 711.15 (11.83) (34.22) (15.58)
Quick Ratio
6.41 4.44 4.63 4.82 8.56 7.36 6.82 5.56 1.42 2.71
Current Ratio
7.10 4.88 4.98 5.10 8.80 7.53 7.00 5.78 1.46 2.90
Net Debt/EBITDA
1.13 2.81 4.18 (33.29) (9.91) 12.15 5.03 1.40 4.57 1.36
Debt/Assets
34.11% 36.69% 43.93% 31.17% 40.87% 49.34% 47.46% 49.63% 9.45% 29.43%
Debt/Equity
0.68 0.86 1.33 0.69 0.90 1.37 1.28 1.57 0.33 0.70
Asset Turnover
0.28 0.65 0.82 0.86 0.65 0.49 0.46 0.44 0.51 0.64
Operating CF/Net income
0.82 0.54 0.03 (3.68) 5.01 (1.42) (0.33) 0.35 0.16 0.36
Capex/Depreciation
(3.04) (0.93) (0.67) (1.67) (1.21) (1.81) (2.35) 2.24 2.97 3.09
Interest Coverage
(18.76) (4.29) (2.74) (0.12) 2.47 (5.73) 11.66 5.66 4.33 8.76
ROE
(67.07%) (48.19%) (56.29%) (4.38%) 5.71% (13.16%) (21.73%) (51.52%) (46.67%) (38.89%)
ROA
(44.74%) (22.53%) (21.01%) (1.77%) 2.59% (5.33%) (7.94%) (17.71%) (14.13%) (13.32%)
ROIC
(385.93%) (96.51%) (155.72%) (1.46%) 36.29% (81.01%) (152.27%) (767.68%) 0.00% (80.34%)
Return on Tangible Assets
(54.12%) (28.95%) (23.35%) (1.95%) 2.18% (6.04%) (9.27%) (22.55%) (38.09%) (26.04%)
Average Days of Receivables
72.32 77.67 74.75 91.49 87.08 75.45 76.16 60.12 65.91 82.49
Research and Development Expense of Revenue
50.03% 21.52% 20.39% 22.49% 26.70% 37.62% 38.32% 43.79% 34.64% 34.26%
Selling, General and Administrative Expense of Revenue
133.26% 69.28% 60.92% 52.55% 45.60% 49.19% 56.97% 76.74% 70.87% 63.74%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
26.71% 15.32% 16.06% 14.92% 15.32% 17.74% 19.89% 22.70% 26.44% 16.00%
Graham Net Nets
0.18 0.05 0.03 0.02 0.02 0.04 0.05 0.16 0.07 0.13
Graham Number
0.00 0.00 0.00 0.00 4.61 0.00 0.00 0.00 0.00 0.00
Earnings Yield
(19.75%) (3.45%) (2.09%) (0.09%) 0.12% (0.75%) (1.30%) (13.54%) (5.23%) (9.44%)
Free Cash Flow Yield
(18.65%) (2.25%) (0.28%) 0.20% 0.48% 0.75% 0.13% (6.56%) (2.15%) (5.25%)
Revenue per Share
0.97 2.00 2.70 3.61 4.90 5.17 5.14 4.79 5.61 5.88
Operating CF per Share
(1.26) (0.37) (0.02) 0.27 0.98 0.80 0.29 (0.69) (0.24) (0.44)
Capex per Share
(0.21) (0.08) (0.07) (0.11) (0.15) (0.23) (0.20) (0.25) (0.40) (0.24)
Free Cash Flow per Share
(1.46) (0.46) (0.09) 0.17 0.83 0.57 0.09 (0.94) (0.64) (0.68)
Cash per Share
2.57 2.09 2.70 3.38 8.46 9.07 9.27 8.58 8.92 4.10
Shareholders Equity per Share
1.66 1.28 1.22 2.24 4.72 3.97 4.22 3.41 3.34 3.05
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
1.66 1.28 1.22 2.24 4.72 3.97 4.22 3.41 3.34 3.05
Free Cash Flow
(125.26) (40.50) (8.58) 16.14 84.18 58.59 9.43 (100.43) (69.22) (75.68)
Working Capital
224.99 194.93 256.81 353.64 885.83 930.92 952.75 855.29 350.18 423.50
Capital Expenditures
(17.66) (7.37) (6.71) (10.48) (14.97) (24.17) (21.36) (27.09) (42.85) (26.65)
Net Current Asset Value
122.14 93.40 93.84 178.29 423.98 344.53 361.05 250.78 225.97 182.87
EV/EBIT
0.00 0.00 0.00 0.00 560.54 0.00 0.00 0.00 0.00 0.00
Capex to Sales
0.21 0.04 0.03 0.03 0.03 0.05 0.04 0.05 0.07 0.04
Price to Operating Income
0.00 0.00 0.00 0.00 574.49 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.31 0.44 0.65 0.37 0.55 0.37 0.20 (0.19) (0.16) (0.09)
Cash ROIC
(27.32%) (10.22%) (1.68%) 2.32% 4.78% 3.07% 0.48% (5.45%) (4.81%) (7.31%)
Accounts Receivable Turnover
6.09 6.55 5.61 5.06 4.80 4.68 4.83 5.19 6.27 5.09
Accounts Payable Turnover
2.64 3.13 3.65 2.78 2.35 1.82 1.46 1.43 1.38 1.47
Inventory Turnover
2.36 2.34 3.59 3.83 4.17 4.43 4.27 3.80 3.75 4.38
Average Days of Payables
144.76 112.93 121.78 152.11 183.86 230.67 270.72 268.57 279.60 267.35
Days of Inventory on Hand
201.49 144.57 102.85 97.63 93.98 77.61 93.34 108.56 93.35 89.92
Average Receivables
13.61 27.05 44.24 69.43 103.00 114.27 111.41 98.06 96.59 128.70
Average Payables
17.56 17.78 21.96 31.82 45.29 63.12 78.90 89.79 99.74 113.66
Average Inventory
19.57 23.79 22.29 23.13 25.56 25.92 26.90 33.76 36.62 38.10
Average Assets
294.71 273.69 302.55 409.62 765.72 1,095.74 1,165.57 1,168.89 1,193.46 1,022.56
Average Common Equity
196.58 127.95 112.91 165.02 347.16 443.51 425.83 401.83 361.34 350.32

Fold the line items

Columns are period end dates